Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stockGufic BioSciences Ltd (GUFICBIO) is currently trading at 365.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gufic Biosciences Limited is a research‑based pharmaceutical company and one of India’s largest manufacturers of lyophilized injections, operating multiple WHO/EU/ANVISA/MHRA/USFDA‑standard facilities across Navsari, Belgaum and Indore, with domestic branded segments, CMO services, API manufacturing and an expanding international registration footprint across regulated and semi‑regulated markets. Indore commissioning materially increases global injectable capacity and is being validated via a phased, compliance‑first approach; management expects Indore to be EBITDA breakeven at ~30% utilization and to unlock export volumes that will de‑bottleneck Navsari and lift regulated‑market sales, while they deliberately manage scaling to preserve audit readiness and quality. Gufic is shifting international strategy from distributor‑led sales to IP‑owned, complex injectables with direct marketing authorization capability; recent EU registrations and Gufic Ireland’s first EU MA demonstrate intent to monetize high‑value molecules across Europe, LATAM and regulated geographies via licensing and tech‑transfer. Financially, Q3 FY26 revenue was INR231.1 crore with EBITDA INR37.1 crore (16.05% margin) and 9M FY26 revenue near INR688–692 crore; management cites one‑time receivable corrections to improve working capital, a consolidated debt profile around INR375 crore, and conservative guidance of at least 15% revenue growth for FY27.
Over the past 52 weeks, Gufic BioSciences Ltd has traded between a low of ₹267.50 and a high of ₹409.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gufic BioSciences Ltd has a market capitalization of approximately 3,890.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gufic BioSciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 60.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,890.46 Cr, Gufic BioSciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gufic BioSciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gufic BioSciences Ltd is 60.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Earnings Call Transcript
Q4 revenue ~INR252 crore; EBITDA ~INR44.7 crore (17.7% margin) and PAT more than doubled YoY; FY26 revenue ~INR940 crore and PAT INR63 crore; Indore plant reached 30% utilization and EBITDA breakeven; EU GMP certificate pending; shift to holding MAs internationally with multiple approvals, 18 new filings and a global-health partner covering procurement across 109 countries.
Earnings Transcript
Transcript summarizing Q4 revenue ~INR252cr, EBITDA ~INR44.7cr (17.7%), FY26 revenue ~INR940cr with PAT INR63cr; Indore facility reached 30% utilization and EBITDA breakeven; EU GMP audit done; international MA-led strategy progressing.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1211.20 | 4,195 Cr | — | 6.05 | 0.00 | -10.66 | -6.48 | -6.55 | ||
132.90 | 3,901 Cr | 26.74 | 2.17 | 0.75 | 7.65 | 10.29 | 5.32 | ||
387.95 | 3,890 Cr | 60.62 | 5.85 | 0.03 | 9.66 | 11.45 | 4.78 | ||
608.45 | 3,727 Cr | — | 4.46 | 0.00 | -2.93 | -2.42 | -0.57 | ||
377.00 | 3,535 Cr | 34.66 | 4.50 | 0.11 | 12.98 | 12.14 | 6.46 | ||
2093.25 | 3,464 Cr | 30.86 | 5.72 | 1.15 | 19.03 | 24.66 | 14.52 | ||
374.00 | 3,443 Cr | 17.66 | 2.22 | 0.00 | 12.58 | 11.51 | 6.92 | ||
| Median: 7 Co. | — | 387.95 | 3,727 Cr | 30.86 | 4.50 | 0.03 | 9.66 | 11.45 | 5.32 |
Bearish
4
Neutral
6
Bullish
4
Bearish
10
Neutral
6
Bullish
30
Bearish
6
Neutral
0
Bullish
26
Gufic Biosciences Limited is a research‑based pharmaceutical company and one of India’s largest manufacturers of lyophilized injections, operating multiple WHO/EU/ANVISA/MHRA/USFDA‑standard facilities across Navsari, Belgaum and Indore, with domestic branded segments, CMO services, API manufacturing and an expanding international registration footprint across regulated and semi‑regulated markets.
Indore commissioning materially increases global injectable capacity and is being validated via a phased, compliance‑first approach; management expects Indore to be EBITDA breakeven at ~30% utilization and to unlock export volumes that will de‑bottleneck Navsari and lift regulated‑market sales, while they deliberately manage scaling to preserve audit readiness and quality.
Gufic is shifting international strategy from distributor‑led sales to IP‑owned, complex injectables with direct marketing authorization capability; recent EU registrations and Gufic Ireland’s first EU MA demonstrate intent to monetize high‑value molecules across Europe, LATAM and regulated geographies via licensing and tech‑transfer.
Financially, Q3 FY26 revenue was INR231.1 crore with EBITDA INR37.1 crore (16.05% margin) and 9M FY26 revenue near INR688–692 crore; management cites one‑time receivable corrections to improve working capital, a consolidated debt profile around INR375 crore, and conservative guidance of at least 15% revenue growth for FY27.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,665 Cr
Low Risk
57.1
34.1
-7.7
5.9
409.00
267.50
Sales CAGR
Profit CAGR
ROE
ROCE
